The Acquired Vulnerability Caused by CDK4/6 Inhibition Promotes Drug Synergism Between Oxaliplatin and Palbociclib in Cholangiocarcinoma

The Acquired Vulnerability Caused by CDK4/6 Inhibition Promotes Drug Synergism Between Oxaliplatin and Palbociclib in Cholangiocarcinoma

Cholangiocarcinoma (CCA) is one of the most difficult to treat cancers, and its nature of being largely refractory to most, if not all, current treatments results in generally poor prognosis and high mortality. Efficacious alternative therapies that can be used ubiquitously are urgently needed. Usin...

Full description

Bibliographic Details
Main Authors: Orawan Suppramote, Sunisa Prasopporn, Satinee Aroonpruksakul, Ben Ponvilawan, Jiradej Makjaroen, Monthira Suntiparpluacha, Krittiya Korphaisarn, Komgrid Charngkaew, Rawisak Chanwat, Trairak Pisitkun, Seiji Okada, Somponnat Sampattavanich, Siwanon Jirawatnotai
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-05-01
Series:Frontiers in Oncology
Subjects:
acquired vulnerability
ribosomal biogenesis stress
CDK4/6 inhibitor
oxaliplatin
cholangiocarcinoma (CCA)
palbociclib
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2022.877194/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2022.877194/full

Similar Items